Genomind’s Post

🌟 Let’s Talk About MA3: The Pillars of Personalized Medicine! 🌟 Medication Adherence. Medication Appropriateness. Medication Adverse Events. 🧬   These three factors—together coined as MA3—represent a new framework for advancing effective and truly personalized care. Think of MA3 as the ultimate checklist for tailoring treatments to improve outcomes, reduce risks, and empower patients.   🔍 Why MA3 Matters: * Adherence: Ensuring patients follow their medication plans for maximum benefit. * Appropriateness: Matching the right medication to the right patient based on their unique biology, environment, and lifestyle. * Adverse Events: Preventing or mitigating side effects with informed prescribing.   In my latest article, I introduce MA3 and explore how it can transform personalized medicine by integrating cutting-edge fields like pharmacogenomics, epigenetics, and nutrigenomics. By using MA3 as a framework, we can make precision healthcare not just a possibility, but a reality. Curious about how this approach could redefine patient care? Read more here: https://lnkd.in/eGBtTB-f   💡 How do YOU see MA3 fitting into the future of healthcare? Drop a comment and join the conversation! #PersonalizedMedicine #MA3 #Pharmacogenomics #PrecisionHealth #ClinicalInnovation  

#Pharmacogenomics uses individual genetic profiles to determine the most effective, safest medications and dosage. This helps ensure that patients are prescribed medications that are the most effective and have the fewest potential side effects. Combining pharmacogenomics data with other information such as a patient's overall health, lifestyle factors and family history can help care teams determine a personalized treatment plan with the right medication and dosage for that individual. Nicklaus Children's Hospital is the first Pediatric Hospital in Florida to adopt innovative Pharmacogenomics Testing Technology to Personalize Patient Treatment Plans. If you want to know more don't miss this webinar!

🌟Great news! Lyric & Concert Expand Partnership to Deliver New Laboratory Payment Accuracy Solution 🧬🔬 For many health plans, infectious disease testing is the largest area of outpatient lab spend. Add to that the rising quantity of tests and costs involved with genetic tests—and we arrive at Lyric's new Diagnostics Module. Lyric's CEO, Rajeev Ronanki shares: “Combining Lyric’s market-leading payment accuracy capabilities with Concert’s data, clinical policies, and AI-powered edits will deliver unparalleled accuracy for our customers and aligns with our strategy to bring best-in-class partner solutions to customers via Lyric’s technology.” Lyric and Concert first partnered in 2023 to deliver an integrated genetic test management solution. The expanded Diagnostics Module is expected to be available to health plan customers in summer 2024.  #labs #paymentaccuracy #healthplans #diagnostics

Just published another great article on the complexities of rare disease therapy manufacturing and logistics in Xtalks Clinical Edge. These patients and their families face unique challenges, as do their healthcare providers, the manufacturers who produce the therapies in massive bioreactors, the regulators who fast track their approval, and specialty logistics providers who deliver them on-time and within specification. They are costly to make and pay for, but there is a light at the end of the tunnel for these patients thanks to collaboration among all stakeholders. #rarediseases #genetherapies #celltherapies Special shout-out to Terra Lewis, Robert Brackner, and Anne-Marie Zia, my co-authors, on this important piece of literature, and to Leanne Boytler and Julia Tarasenko for their expert viewpoints/quotes.

 🧬"𝑳𝒊𝒏𝒅𝒖𝒔 𝑯𝒆𝒂𝒍𝒕𝒉 𝑫𝒆𝒃𝒖𝒕𝒔 "𝑨𝒍𝒍-𝒊𝒏-𝑶𝒏𝒆 𝑫𝒊𝒂𝒈𝒏𝒐𝒔𝒕𝒊𝒄 𝑪𝑹𝑶" 𝑺𝒐𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒐𝒓 𝑫𝒊𝒂𝒈𝒏𝒐𝒔𝒕𝒊𝒄 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑻𝒓𝒊𝒂𝒍𝒔"🔬 Lindus Health, the "anti-CRO", have announced today that they have launched CRO offerings tailor-made for sponsors focused on bringing diagnostic products to market. This offering combines expert CRO services and vast experience for diagnostic clinical trials, with their repository of over 30 million electronic health records and their internal eClinical platform Citrus™, to amalgamate everything diagnostic sponsors need to conduct these studies in one place. 𝐂𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐩𝐫𝐞𝐬𝐬 𝐫𝐞𝐥𝐞𝐚𝐬𝐞, 𝐋𝐢𝐧𝐝𝐮𝐬 𝐇𝐞𝐚𝐥𝐭𝐡 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐧𝐞𝐰 𝐨𝐟𝐟𝐞𝐫𝐢𝐧𝐠 𝐨𝐮𝐭 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 👇 #diagnostics #CRO #contractresearch #clinicaltrials #Dx

Emicizumab brings hope to Haemophilia A patients, accessibility remains a challenge According to experts, Emicizumab prophylaxis is considered to be a far superior and effective way of managing Haemophilia A in comparison to other traditional treatment options. Current treatment options of ODT like Factor VIII replacement, FVIII concentrates and bypass agents that prevail in the market are sub-optimal inadequate. #Haemophilia | #FVIIIConcentrates | #SubOptimalInadequate | #Emicizumabprophylaxis | #Healthnews | Prathiba Raju | Nita Radhakrishnan | Dr. Rahul Bhargava | Roche | Fortis Memorial Research Institute - India | Read more:

By partnering with Infopoly, Pain Cloud® has become an automated platform with the development of a back-end tech stack via integrated novel software. The platform accesses huge data sets from high-quality molecular databases, linking research targets to optimized disease phenotypes. Here’s what our CEO and Co-Founder Mark J. Field has to say about our partnership with Infopoly: “By utilising Pain Cloud®, researchers can avoid the challenges of cost-intensive traditional R&D methodologies with a streamlined process, precisely matching targets and mechanisms to specific patient groups and saving time.” Read more about how Pain Cloud® can set you on the path towards greater success in clinical development: https://lnkd.in/eEVuXywq #TargetValidation #PainResearch #Analgesics #Therapeutics #ClinicalDevelopment

Excellent data for ATAI Life Sciences AG's & their subsidiary Beckley Psytech's Phase 2a open label study of BPL-003 (intranasal 5-MeO-DMT) in patients who suffer from treatment-resistant depression (TRD). In summary, the Phase 2a results of BPL-003 demonstrated: 1) Rapid-acting relief: a single dose of BPL-003 demonstrated a rapid antidepressant response in over half of the patients. 2) Durable antidepressant effect: 45% of patients were in remission 3 months after a single dose. This is the longest reported improvement following 5-MeO-DMT treatment in a clinical setting. 3) Short treatment time: The acute effects of BPL-003 resolved within an average of less than 2 hours, offering encouraging support for a 2-hour psychedelic-based treatment in the clinic (as pioneered by Spravato). More data to come from the larger Phase 2b study of BPL-003 in 225 TRD patients, anticipated in the second half of this year. #investing #future https://lnkd.in/ghu2Pdxh

In clinical research, ensuring accurate medication adherence is crucial for obtaining reliable trial results. Unfortunately, many trials overlook this aspect, potentially affecting outcomes. Med-ic smart blisters revolutionize this space by offering state-of-the-art, independent, and objective medication dosing data. It's time to make these tools a mandatory element in clinical studies to enhance data accuracy and trial integrity. Explore more about current challenges in clinical trials: www.certiscan.biz

This prospective study aimed to collect “real-life” clinical data among a population of patients treated with the pDVA in order to evaluate the clinical effectiveness and safety of the LimFlow System in patients with no-option critical limb ischemia: https://lnkd.in/eshyPw9